Autophagy: novel applications of nonsteroidal anti‐inflammatory drugs for primary cancer

Yu Chen, Weibing Li, Junbao Liu, Jianwei Lu, Jifeng FengCancer Medicine 2017 · DOI

TL;DR

Nonsteroidal anti-inflammatory drugs (NSAIDs), commonly used for pain and inflammation, are showing promise in cancer treatment by modulating autophagy, a cellular self-eating process. This review highlights how NSAIDs can either promote or inhibit autophagy, leading to diverse anti-cancer effects, and suggests their potential as adjunct therapies.

What Problem Does This Paper Address?

For decades, cancer research has primarily focused on apoptosis (programmed cell death). However, resistance to apoptosis has become a major hurdle in cancer treatment. This has spurred interest in other programmed cell death mechanisms, including autophagy. Autophagy, while generally a survival mechanism for cells under stress, can also induce cell death. The problem this paper addresses is understanding how NSAIDs, a widely available class of drugs, interact with autophagy and how this interaction can be leveraged for cancer therapy, particularly in cases of drug resistance.

Methods

This paper is a review, synthesizing existing research rather than presenting new experimental data. The authors analyze findings from numerous studies that investigated the effects of various NSAIDs (celecoxib, meloxicam, sulindac, aspirin, etc.) on cancer cells and animal models. They focus on:

  • Molecular Mechanisms: Examining how NSAIDs influence key signaling pathways involved in autophagy, such as PI3K/Akt/mTOR, MAPK/ERK1/2, P53/DRAM, and AMPK/mTOR.
  • Biomarker Analysis: Investigating the role of specific proteins like Beclin-1, LC3-II, p62, and Atg5-12 in mediating NSAID-induced autophagy.
  • Cellular Response: Differentiating between NSAIDs that induce cytoprotective (survival) autophagy and those that induce tumor-suppressing (death-inducing) autophagy.
  • Therapeutic Combinations: Reviewing studies that combine NSAIDs with chemotherapy or radiotherapy to enhance treatment efficacy.

Datasets

Not discussed in the paper. This is a review article, summarizing existing literature.

Key Insights and Ideas

  • Autophagy's Dual Role: Autophagy isn't simply "good" or "bad" for cancer. Its effect can be context-dependent, acting as a survival mechanism for tumor cells or, under certain conditions, promoting cell death.
  • NSAIDs as Autophagy Modulators: NSAIDs are not just anti-inflammatory agents; they can directly influence the autophagy pathway. This modulation can be either pro-autophagic (inducing autophagy) or anti-autophagic (inhibiting autophagy).
  • Dose and Duration Matter: The effect of NSAIDs on autophagy and cancer cell fate (apoptosis vs. autophagy) can be significantly influenced by the concentration and duration of drug exposure. Low doses/short-term use might promote autophagy, while high doses/long-term use might switch to apoptosis.
  • Targeting Specific Pathways: NSAIDs can modulate autophagy through various signaling cascades, including the critical PI3K/Akt/mTOR pathway, which is a central regulator of cell growth and survival.
  • Potential for Combination Therapy: NSAIDs, particularly celecoxib, show promise when combined with existing chemotherapy drugs or radiotherapy, potentially overcoming drug resistance and enhancing treatment outcomes.
  • p53's Crucial Role: The tumor suppressor protein p53 appears to play a significant role in mediating NSAID-induced autophagy, particularly in inhibiting tumor cell viability.

Key Results

The review highlights that NSAIDs can:

  • Induce Tumor-Suppressing Autophagy: Studies show NSAIDs like celecoxib, meloxicam, and aspirin can enhance autophagy, leading to cell cycle arrest and apoptosis in various cancer cell lines and animal models. This is often mediated by pathways involving Beclin-1, LC3-II, and p62 degradation.
  • Induce Cytoprotective Autophagy: In some contexts, NSAIDs can inhibit lysosome function, leading to autophagy that helps cancer cells survive stress, as seen with celecoxib in certain leukemia cell lines.
  • Enhance Radiosensitivity and Chemotherapy Efficacy: NSAID-induced autophagy can sensitize cancer cells to radiotherapy and chemotherapy, especially in drug-resistant tumors.
  • Modulate ER Stress: Celecoxib, for instance, can induce endoplasmic reticulum (ER) stress, which in turn can activate autophagy as a protective mechanism, but also contribute to cell death under certain conditions.

Limitations and Future Work

  • Complexity of Autophagy: The paper acknowledges that the role of autophagy in cancer is complex and context-dependent, influenced by tumor type, stage, microenvironment, and genetic factors.
  • Predicting Patient Response: A key unanswered question is identifying which patients will benefit most from NSAID-based therapies and how to optimize treatment strategies.
  • Mechanism of p53-Dependent Autophagy: While the involvement of p53 is noted, the precise mechanisms of p53-dependent autophagy induced by NSAIDs require further clarification.
  • Optimal Dosing and Timing: Determining the ideal dosage, duration, and timing of NSAID administration for different cancer types and treatment combinations is crucial and requires further investigation.
  • Side Effects: While NSAIDs are generally well-understood, potential side effects (e.g., cardiovascular risks with selective COX-2 inhibitors) need careful consideration in therapeutic applications.

Future research should focus on unraveling these complexities to develop targeted and effective NSAID-based cancer therapies.

Summary updated

Abstract

In eukaryotic cells, autophagy is a process associated with programmed cell death. During this process, cytoplasmic proteins and organelles are engulfed by double-membrane autophagosomes, which then fuse with lysosomes to form autolysosomes. These autolysosomes then degrade their contents to recycle the cellular components. Autophagy has been implicated in a wide variety of physiological and pathological processes that are closely related to tumorigenesis. In recent years, an increasing number of studies have indicated that nonsteroidal anti-inflammatory drugs, such as celecoxib, meloxicam, sulindac, aspirin, sildenafil, rofecoxib, and sodium salicylate, have diverse effects in cancer that are mediated by the autophagy pathway. These nonsteroidal anti-inflammatory drugs can modulate tumor autophagy through the PI3K/Akt/mTOR, MAPK/ERK1/2, P53/DRAM, AMPK/mTOR, Bip/GRP78, CHOP/ GADD153, and HGF/MET signaling pathways and inhibit lysosome function, leading to p53-dependent G1 cell-cycle arrest. In this review, we summarize the research progress in autophagy induced by nonsteroidal anti-inflammatory drugs and the molecular mechanisms of autophagy in cancer cells to provide a reference for the potential benefits of nonsteroidal anti-inflammatory drugs in cancer chemotherapy.
BibTeX
@inproceedings{chen2017autophagy,
  author = {Yu Chen and Weibing Li and Junbao Liu and Jianwei Lu and Jifeng Feng},
  title = {{Autophagy: novel applications of nonsteroidal anti‐inflammatory drugs for primary cancer}},
  booktitle = {Cancer Medicine},
  year = {2017},
  doi = {10.1002/cam4.1287},
}
Figure